Table 2.

Demographics of Participants Per Aβ Group

	Aβ−	Aβ−+	Aβ++
Number of participants, n
Total	116	18	14
Baseline	100	16	14
Follow-up	76	15	5
Age (y), mean ± SD
Baseline	70.08 ± 5.81	69.04 ± 6.18	73.18 ± 4.54
Follow-up	72.29 ± 5.88	71.18 ± 6.17	75.44 ± 4.55
Female sex (%)	53	44	71
Time between follow-up (y), mean ± SD	2.33 ± 0.36	2.32 ± 0.48	2.69 ± 0.53
Time between PET scans (y), mean ± SD	4.29 ± 0.39	4.34 ± 0.54	4.45 ± 0.50
Average MMSE, mean ± SD
Baseline	28.70 ± 1.35	28.33 ± 1.64	28.29 ± 1.38
Follow-up	28.88 ± 1.03	28.89 ± 1.50	28.30 ± 2.11
Hypertension (%)
Baseline	47	55.6	28.6
Follow-up	36.8	55.6	14.3
Hypercholestermia (%)
Baseline	32.5	44.4	35.7
Follow-up	36.8	55.6	35.7
Diabetes (%)
Baseline	6.8	0	7.1
Follow-up	6.8	0	7.1
Angina (%)
Baseline	5.1	0	0
Follow-up	7.7	0	0
Atherosclerosis (%)
Baseline	2.6	0	0
Follow-up	4.3	0	0
Myocardial infarct (%)
Baseline	4.3	0	0
Follow-up	6.8	0	0
Transient ischemic attack (%)
Baseline	2.6	0	7.1
Follow-up	2.6	0	7.1
Macula signal strength, mean ± SD
Baseline	9.2 ± 1	9.4 ± 0.96	9.0 ± 1
Follow-up	9.1 ± 0.76	9.1 ± 0.71	9.0 ± 0.61
Optic nerve signal strength, mean ± SD
Baseline	9.4 ± 0.75	9.2 ± 0.94	9.6 ± 0.77
Follow-up	9.0 ± 0.80	9.2 ± 0.54	9.3 ± 0.27